bluebird bio Inc (NAS:BLUE)
$ 0.4171 0.0121 (2.99%) Market Cap: 81.10 Mil Enterprise Value: 376.50 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 31/100

bluebird bio Inc at Goldman Sachs Healthcare Conference Transcript

Jun 12, 2023 / 11:40PM GMT
Release Date Price: $3.5 (-4.11%)
Salveen Jaswal Richter
Goldman Sachs Group, Inc., Research Division - VP

Good afternoon. Thanks, everyone, for joining us. I'm Salveen Richter, biotechnology analyst at Goldman Sachs, and we're really pleased to have the bluebird team with us. So we have Andrew Obenshain, CEO; and we have Tom Klima, Chief Commercial and Operating Officer.

Questions & Answers

Salveen Jaswal Richter;Andrew
Goldman Sachs Group, Inc., Research Division - VP

So to start here, it's been a really busy time for you guys given the launch of 2 drugs and 2 different indications here with the potential for a third in sickle cell to come. So just help us understand maybe starting with ZYNTEGLO, and we can go through these programs. But it's approved in August of last year, and the first patient was infused in April. So can you just walk us through your launch strategy and how it's -- if it has changed at all during the period and the process and where bottlenecks have been or -- and where they've maybe been alleviated and kind of where you stand today with that?

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot